96 related articles for article (PubMed ID: 15019163)
21. Altered expression and loss of heterozygosity of the LOT1 gene in ovarian cancer.
Cvetkovic D; Pisarcik D; Lee C; Hamilton TC; Abdollahi A
Gynecol Oncol; 2004 Dec; 95(3):449-55. PubMed ID: 15581945
[TBL] [Abstract][Full Text] [Related]
22. Genome-wide SNP analysis of Tg.AC transgenic mice reveals an oncogenic collaboration between v-Ha-ras and Ink4a, which is absent in p53 deficiency.
Leder A; McMenamin J; Zhou F; Moran JL; Beier DR; Leder P
Oncogene; 2008 Apr; 27(17):2456-65. PubMed ID: 17952114
[TBL] [Abstract][Full Text] [Related]
23. Knockdown of p53 levels in human keratinocytes accelerates Mcl-1 and Bcl-x(L) reduction thereby enhancing UV-light induced apoptosis.
Chaturvedi V; Sitailo LA; Qin JZ; Bodner B; Denning MF; Curry J; Zhang W; Brash D; Nickoloff BJ
Oncogene; 2005 Aug; 24(34):5299-312. PubMed ID: 15940268
[TBL] [Abstract][Full Text] [Related]
24. Expression of full-length p53 and its isoform Deltap53 in breast carcinomas in relation to mutation status and clinical parameters.
Baumbusch LO; Myhre S; Langerød A; Bergamaschi A; Geisler SB; Lønning PE; Deppert W; Dornreiter I; Børresen-Dale AL
Mol Cancer; 2006 Oct; 5():47. PubMed ID: 17054774
[TBL] [Abstract][Full Text] [Related]
25. Differentially regulated micro-RNAs and actively translated messenger RNA transcripts by tumor suppressor p53 in colon cancer.
Xi Y; Shalgi R; Fodstad O; Pilpel Y; Ju J
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2014-24. PubMed ID: 16609010
[TBL] [Abstract][Full Text] [Related]
26. The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells.
Phan RT; Dalla-Favera R
Nature; 2004 Dec; 432(7017):635-9. PubMed ID: 15577913
[TBL] [Abstract][Full Text] [Related]
27. HRK inactivation associated with promoter methylation and LOH in prostate cancer.
Higuchi T; Nakamura M; Shimada K; Ishida E; Hirao K; Konishi N
Prostate; 2008 Jan; 68(1):105-13. PubMed ID: 18008329
[TBL] [Abstract][Full Text] [Related]
28. Differentiating human keratinocytes are deficient in p53 but retain global nucleotide excision repair following ultraviolet radiation.
Oh DH; Yeh K
DNA Repair (Amst); 2005 Sep; 4(10):1149-59. PubMed ID: 16043423
[TBL] [Abstract][Full Text] [Related]
29. Allele-specific loss of heterozygosity at the DAL-1/4.1B (EPB41L3) tumor-suppressor gene locus in the absence of mutation.
Kittiniyom K; Mastronardi M; Roemer M; Wells WA; Greenberg ER; Titus-Ernstoff L; Newsham IF
Genes Chromosomes Cancer; 2004 Jul; 40(3):190-203. PubMed ID: 15138999
[TBL] [Abstract][Full Text] [Related]
30. Thirteen new p53 gene mutants identified among 41 human breast cancer cell lines.
Wasielewski M; Elstrodt F; Klijn JG; Berns EM; Schutte M
Breast Cancer Res Treat; 2006 Sep; 99(1):97-101. PubMed ID: 16541312
[TBL] [Abstract][Full Text] [Related]
31. Immunohistochemical and biogenetic features of diffuse-type tenosynovial giant cell tumors: the potential roles of cyclin A, P53, and deletion of 15q in sarcomatous transformation.
Huang HY; West RB; Tzeng CC; van de Rijn M; Wang JW; Chou SC; Huang WW; Eng HL; Lin CN; Yu SC; Wu JM; Lu CC; Li CF
Clin Cancer Res; 2008 Oct; 14(19):6023-32. PubMed ID: 18829481
[TBL] [Abstract][Full Text] [Related]
32. A SNP in the flt-1 promoter integrates the VEGF system into the p53 transcriptional network.
Menendez D; Krysiak O; Inga A; Krysiak B; Resnick MA; Schönfelder G
Proc Natl Acad Sci U S A; 2006 Jan; 103(5):1406-11. PubMed ID: 16432214
[TBL] [Abstract][Full Text] [Related]
33. PHTS, a novel putative tumor suppressor, is involved in the transformation reversion of HeLaHF cells independently of the p53 pathway.
Yu DH; Fan W; Liu G; Nguy V; Chatterton JE; Long S; Ke N; Meyhack B; Bruengger A; Brachat A; Wong-Staal F; Li QX
Exp Cell Res; 2006 Apr; 312(6):865-76. PubMed ID: 16413018
[TBL] [Abstract][Full Text] [Related]
34. Loss of CDKN2A and p14ARF expression occurs frequently in human nonmelanoma skin cancers.
Pacifico A; Goldberg LH; Peris K; Chimenti S; Leone G; Ananthaswamy HN
Br J Dermatol; 2008 Feb; 158(2):291-7. PubMed ID: 18070208
[TBL] [Abstract][Full Text] [Related]
35. Cutaneous hidradenocarcinoma: a clinicopathological, immunohistochemical, and molecular biologic study of 14 cases, including Her2/neu gene expression/amplification, TP53 gene mutation analysis, and t(11;19) translocation.
Kazakov DV; Ivan D; Kutzner H; Spagnolo DV; Grossmann P; Vanecek T; Sima R; Kacerovska D; Shelekhova KV; Denisjuk N; Hillen U; Kuroda N; Mukensnabl P; Danis D; Michal M
Am J Dermatopathol; 2009 May; 31(3):236-47. PubMed ID: 19384064
[TBL] [Abstract][Full Text] [Related]
36. Targeted inactivation of p53 in human cells does not result in aneuploidy.
Bunz F; Fauth C; Speicher MR; Dutriaux A; Sedivy JM; Kinzler KW; Vogelstein B; Lengauer C
Cancer Res; 2002 Feb; 62(4):1129-33. PubMed ID: 11861393
[TBL] [Abstract][Full Text] [Related]
37. Expression of p53 protein in pterygium.
Onur C; Orhan D; Orhan M; Dizbay Sak S; Tulunay O; Irkeç M
Eur J Ophthalmol; 1998; 8(3):157-61. PubMed ID: 9793769
[TBL] [Abstract][Full Text] [Related]
38. [Expression of p53 and flow cytometric analysis of DNA index and S-phase fraction in pterygium].
Sang AM; Lu H
Zhonghua Yi Xue Za Zhi; 2010 Jul; 90(27):1890-2. PubMed ID: 20979905
[TBL] [Abstract][Full Text] [Related]
39. Pathogenetic mechanisms and treatment options for ophthalmic pterygium: trends and perspectives (Review).
Detorakis ET; Spandidos DA
Int J Mol Med; 2009 Apr; 23(4):439-47. PubMed ID: 19288018
[TBL] [Abstract][Full Text] [Related]
40. Progress in the pathogenesis of pterygium.
Liu T; Liu Y; Xie L; He X; Bai J
Curr Eye Res; 2013 Dec; 38(12):1191-7. PubMed ID: 24047084
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
